Skip to main content
. 2015 Aug 1;15:566. doi: 10.1186/s12885-015-1571-8

Table 1.

Studies enrolled in this meta-analysis

Study Year Study design Method Cases Follow-up (mos.) Recurrence (%) Progression (%) Quality assessmenta
NIT WLC NIT WLC NIT WLC NIT WLC
Riedl [8] 2001 RCT 5-ALA 51 51 NA NA 22 (45.8) 31 (66) 1 (2) 1 (2) 3
Filbeck [9] 2002 RCT 5-ALA 88 103 21 21 10 (11.4) 29 (28.2) 2 (2.3) 2 (1.9) 3
Kriegmair [10] 2002 RCT 5-ALA 65 64 NA NA 17 (32.7) 26 (53.1) NA NA 2
Babjuk [11] 2005 RCT 5-ALA 60 62 21 22 5 (8.3) 23 (37.1) 5 (8.3) 5 (8.1) 3
Schumacher [12] 2010 RCT 5-ALA 138 141 12 12 NA NA 14 (10.1) 15 (10.6) 1
Stenzl [13] 2011 RCT 5-ALA 271 280 12 21 128 (47.2) 157 (56.1) 5 (1.8) 7 (2.5) 0
Dragoescu [14] 2011 RCT HAL 22 22 9 9 4 (18.2) 10 (45.5) 1 (4.5) 2 (9.1) 3
Hermann [15] 2011 RCT HAL 77 68 12 12 18 (30.5) 35 (47.3) 14 (34.1) 17 (37.8) 3
Stenzl [16] 2010 RCT HAL 183 176 12 12 NA NA 19 (10.4) 19 (10.8) 1
Geavlete [17] 2012 RCT HAL 125 114 24 24 39 (66.1) 52 (70.3) 5 (4) 8 (7) 1
Karaolides [18] 2012 RCT HAL 41 45 18 18 7 (17.1) 18 (40) NA NA 4
Geavlete [19] 2012 RCT NBI 110 110 12 12 7 (6.4) 16 (14.5) NA NA 3
Montanari [20] 2012 RCT NBI 47 45 NA NA 16 (34) 22 (48.9) NA NA 4
Naselli [21] 2012 RCT NBI 76 72 12 12 25 (32.9) 37 (51.4) NA NA 0
Lee [22] 2014 RCT NBI 33 35 16 15 5 (15.2) 8 (22.9) 1 (3) 2 (5.7) 1

NIT new image technology, WLC white light cystoscopy, RCT randomized controlled trial, NA not applicable, 5-ALA 5-aminolaevulinic acid, HAL hexylaminolevulinate, NBI narrow band imaging

aQuality assessment was based on Cochrane’s risk of bias as a quality assessment tool for RCTs. If four or more domains are deemed “unclear” or “no,” the study was classified as having a high risk of bias. If two or three domains were deemed “unclear” or “no,” the study was classified as having a moderate risk of bias